Almanac Health Secures $10M Seed Funding Led by F-Prime

Why It Matters

The infusion of capital enables rapid scaling of a safe, evidence‑grounded AI tool that can reduce clinician reliance on biased sources and accelerate adoption across health systems.

Key Takeaways

• $10M seed round led by F‑Prime, with General Catalyst, Lightspeed.
• Total funding reaches nearly $12M, fueling product development and market expansion.
• Platform delivers specialist‑grade, ad‑free decision support integrated into EHRs.
• Founder introduced retrieval‑augmented generation to clinical medicine at Stanford.
• Clinical AI validated through peer‑reviewed research, enhancing credibility.

Pulse Analysis

The infusion of $10 million into Almanac Health reflects a broader surge of venture capital toward clinical artificial intelligence. Investors such as F‑Prime, General Catalyst, and Lightspeed have earmarked funds for startups that can demonstrate both technical rigor and regulatory compliance, a combination that has historically limited AI adoption in hospitals. Founder Cyril Zakka, MD, leveraged his Stanford research on retrieval‑augmented generation—a technique that blends large language models with curated medical literature—to create a platform that promises more reliable, context‑aware recommendations than generic chat‑based tools.

Almanac’s platform distinguishes itself by delivering specialist‑grade knowledge directly at the point of care, free from pharmaceutical advertising and governed by institutional controls. Seamless integration with existing electronic health record systems allows clinicians to query the AI without leaving their workflow, reducing friction and encouraging adoption. Each recommendation is anchored in peer‑reviewed studies, providing a transparent evidence trail that satisfies both clinicians’ demand for rigor and health systems’ compliance requirements. This evidence‑based approach positions the company to address a critical gap where many AI tools rely on opaque training data.

The new capital will accelerate product refinement, expand integrations, and support clinical trials that validate outcomes across multiple specialties. As hospitals seek to replace legacy decision‑support modules with AI that can keep pace with rapidly evolving guidelines, Almanac’s evidence‑grounded model could become a preferred vendor, especially among institutions wary of commercial bias. The involvement of seasoned investors signals confidence that the market will reward AI solutions that combine scientific validation with seamless EHR embedding, setting a benchmark for future health‑tech fundraising rounds.

Deal Summary

Almanac Health, a clinical AI platform, raised $10 million in a seed round led by F-Prime, with participation from General Catalyst and Lightspeed Venture Partners. The funding brings the company's total capital to nearly $12 million and will accelerate its mission to deliver evidence‑grounded AI to clinicians and health systems.